左旋卡尼汀联合环磷酰苷葡胺治疗维持性血液透析并心力衰竭30例的短期疗效观察

目的观察左旋卡尼汀联合环磷酰苷葡胺治疗维持性血液透析并心力衰竭患者的短期疗效及安全性。方法将60例维持性血液透析并心力衰竭的住院患者根据随机数字表法分为对照组和治疗组各30例,均给予抗感染、强心、扩张血管等常规治疗,对照组静注环磷酰苷葡胺,治疗组静注左旋卡尼汀及环磷酰苷葡胺,治疗均1周。观察治疗前、后心功能改善情况。结果两组均能有效地改善心功能、提高左室射血分数、减慢心率,与治疗前比较差异均有统计学意义(P<0.05);治疗组疗效优于对照组,差异有统计学意义(P<0.05)。结论左旋卡尼汀联合环磷酰苷葡胺治疗维持性血液透析并心力衰竭患者短期疗效好。

环磷酰苷葡胺与1,6二磷酸果糖治疗小儿心肌炎临床疗效

目的观察环磷酰苷葡胺与1,6二磷酸果糖治疗小儿心肌炎的疗效,探讨最佳治疗方案。方法将235例病毒性心肌炎患儿随机分为治疗组115例,对照组120例。两组患儿采用抗感染、卧床休息、镇静及静滴维生素C治疗,治疗组在此基础上加环磷酰苷葡胺10~30 mg/d和1,6二磷酸果糖150 mg/（kg·d）。对照组在此基础上加水溶性维生素1/3-1支和辅酶Q105-10 mg/d。两组疗程均为10 d,观察两组治疗效果。结果患儿症状、体征、心肌酶谱变化方面,对照组和治疗组的总有效率分别为78.33%、92.17%,治疗组患者总有效率显著优于对照组,差异有统计学意义（P〈0.05）。治疗组心肌酶恢复总有效率96.52%,对照组为80.83%,治疗组显著由于对照组,差异有统计学意义（P〈0.05）。结论环磷酰苷葡胺与1,6二磷酸果糖治疗小儿心肌炎效果明显,值得临床推广应用。

环磷酰苷葡胺注射液治疗心功能不全121例分析

目的：观察环磷酰苷葡胺注射液治疗充血性心力衰竭的疗效。方法：将243例充血性心力衰竭患者随机分为两组：观察组121例，对照组122例。对照组患者给予地高辛0．125-0．25mg或西地兰0．2mg加入注射用水20ml，每日1—2次静推，利尿剂给予速尿20—40mg。隔日口服或静推，同时补钾3次／日，疗程4—8周。观察组在应用上述药物的基础上，给予5％葡萄糖200—500ml加入环磷酰苷葡胺注射液60-80mg，1次／日静点，或25％葡萄糖加入环磷酰苷胺注射液90mg 1次／日静推，疗程4—8周。结果：两组心功能较治疗前明显改善。结论：环磷酰苷胺治疗充血性心力衰竭疗效确切，安全可靠，值得临床推广应用。

环磷酰苷葡胺加1,6-二磷酸果糖治疗小儿病毒性心肌炎的效果观察

目的观察小儿病毒性心肌炎患儿治疗中联合应用环磷酰苷葡胺与1,6-二磷酸果糖治疗的有效性。方法选取医院接受治疗的小儿病毒性心肌炎患儿64例,随机分为对照组和观察组,每组32例。对照组采取常规疗法,观察组则在对照组治疗基础上联合环磷酰苷葡胺与1,6-二磷酸果糖治疗,比较2组在护理后的救治耗时、肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(c Tn I)、并发症的发生率、抢救成功率、总体满意率,分析并记录2组治疗前后高频功率(HF)、低频功率(LF)、LF/HF、每5分钟NN间期平均标准差(SDANN)、全部NN期间的标准差(SDNN)、全程相邻NN间期之差的均方根值(RMSSD)、相邻NN间期差值> 50 ms的百分数(PNN50)具体情况。结果观察组护理后救治耗时短于对照组,CK-MB、c Tn I水平低于对照组(P <0. 05);观察组护理后并发症发生率低于对照组,抢救成功率、总体满意率高于对照组(P <0. 05);治疗1个月后,2组HF、LF、SDANN、SDNN、RMSSD、PNN50数值较治疗前均显著改善,且观察组改善情况较对照组显著(P <0. 05)。结论小儿病毒性心肌炎患儿治疗中联合应用环磷酰苷葡胺与1,6-二磷酸果糖可改善患儿各项指标,降低并发症发生率,提高临床治疗有效性,值得推广应用。

环磷腺苷葡胺联合丹参酮ⅡA磺酸钠在肺心病中的临床疗效观察

目的:观察环磷酰苷葡胺联合丹参酮ⅡA磺酸钠在肺心病患者中应用效果。方法:取2016年3月-2017年4月我院收治的肺心病患者60例,随机数字法分为对照组(n=30)和观察组(n=30)。对照组采用环磷酰苷葡胺治疗,观察组联合使用丹参酮ⅡA磺酸钠治疗,比较2组疗效。结果:观察组总有效率为90.00%,明显高于对照组的70.00%(P<0.05);2组治疗前炎症因子水平差异无统计学意义(P>0.05);观察组治疗后10dNO、PaO2水平均高于对照组(P<0.05),ET-1、CRP水平均低于对照组(P<0.05);观察组治疗后血流变学指标如:低切、高切、红细胞聚集指数,显著低于对照组(P<0.05)。结论:肺心病患者在环磷酰苷葡胺基础上联合丹参酮ⅡA磺酸钠治疗效果理想,值得推广应用。

Analysis of Efficacy of DICE(Dexamethasone,Ifosfamide,Cisplatin and Etoposide)Regimen on Recurrent and Refractory Intermediate and High Grade Non-Hodgkin's Lymphoma

OBJECTIVE Thus far there is no standard salvage regimenfor patients with recurrent and refractory intermediate and highgrade non-Hodgkin's lymphoma (NHL). This study intends toinvestigate the therapeutic efficacy of the DICE (dexamethasone,isofosfamide, cisplatin and etoposide) regimen on the recurrentand refractory NHL, and to observe the related adverse effects.METHODS Clinical records of 22 patients with recurrent andrefractory NHL, who failed to achieve a remission from theCHOP [cyclophosphamide, hydroxydaunomycin/doxorubicin(adriamycin), oncovin, prednisone] regimen within 2 to 6 cyclesof treatment, were reviewed. DICE, as a salvage regimen with amedian course of treatment of 4 cycles (ranging from 2 to 7 cycles),was now used, and evaluation of the therapeutic efficacy andadverse effect of DICE was conducted in all the patients. Of the 22NHL cases, 8 were of T-cell origin and the other 14 B-cell origin.Salvage treatment was performed in the patients, with appraisal,prevention and treatment of the toxic reactions.RESULTS Following DICE treatment in the 22 patients, thetotal effective rate of the regimen was 63.6%, and the completeremission (CR) rate was 40.9%. The effective rates of DICE onthe T and B-cell sourced NHL were 75.0% and 57.1%, and the CRrate were 37.5%, 42.9%, respectively (P >0.05). An increase of thelactate dehydrogenase (LDH) level accompanied by a giant lumpwas the short-term effect on patients with recurrence (mean P <0.05) who were drug resistant. Myelosuppression, digestive systemreaction and alopecia were the commonly-seen complications inthe patients who received DICE regimen. All patients recoveredafter treatment, and no chemotherapy-related death occurred.CONCLUSION DICE regimen is effective in treating refractoryand recurrent NHL.

Shenfu injection protects against myelosuppression from chemotherapy

Cyclophosphamide is used to treat a variety of tumors. However, the success of the treatment is limited due to severe myelosuppression caused by cyclophosphamide. Administration of cyclophosphamide could significantly decrease white blood cells （WBCs）, platelets, red blood cells （RBCs）, as well as hemoglobin level. The aim of this research is to investigate the protective role of Shenfu injection against cyclophosphamide induced myelosuppression. The results showed that Shenfu injection can markedly enhance the level of WBCs, platelets, RBCs, and hemoglobin of myelosuppressed rat. The level of WBCs, platelets, RBCs, and hemoglobin were increased by 70%-100%, 80%-90%, 10%-20% and 10%-20%, respectively. Furthermore, the protective role of Shenfu injection against myelosuppression was confirmed by the microscopic observation of bone marrow sections. In conclusion, Shenfu injection has a potential protective effect against cyclophosphamide-induced myelotoxicity.

Synthesis and anti-tumor activities of 5-carbohydrate modified cyclophosphamide derivates

Novel prodrugs of cyclophosphamide 1a and 1b, which comprised the galactosyl moiety, the key fraction of cyclophosphamide derivates, and the linker 4-hydroxy benzaldehyde, were synthesized. These compounds were anticipated to exhibit amplified anti-tumor activity and targeting ability.